Which muscle relaxant is recommended for treating cervical spondylosis?

Muscle Relaxant for Cervical Spondylosis

For cervical spondylosis, skeletal muscle relaxants provide only short-term symptomatic relief (≤2 weeks) for acute neck pain, but gabapentinoids (gabapentin or pregabalin) are preferred first-line agents when radicular symptoms are present.

Evidence Base and Limitations

The evidence supporting muscle relaxants specifically for cervical spondylosis is extremely limited:

• No high-quality trials have directly evaluated muscle relaxants for cervical spondylosis; most evidence extrapolates from acute low back pain studies 1.
• One older randomized trial (n=157) showed eperisone hydrochloride 50 mg three times daily reduced nuchal pain, shoulder pain, and stiffness in cervical spondylosis patients, though this agent is not widely available in many countries 2.
• Skeletal muscle relaxants demonstrate modest benefit for acute musculoskeletal pain only (2-4 days), with a relative risk of 1.25-1.72 for achieving ≥30% pain reduction on visual analog scale compared to placebo 1.

When to Use Muscle Relaxants

Limit use to acute neck pain without radiculopathy for ≤2 weeks maximum:

• Cyclobenzaprine is the most studied agent for acute musculoskeletal conditions and shows moderate superiority to placebo for short-term pain relief 3.
• No single muscle relaxant is superior to others in head-to-head comparisons; selection should be based on side-effect profile and patient comorbidities 4, 5.
• Treatment duration should not exceed 7-14 days, as clinical trials evaluated only 2-week courses and evidence for longer use is absent 4.

Preferred Alternative: Gabapentinoids for Radicular Symptoms

When cervical spondylosis presents with radiculopathy (arm pain, numbness, weakness), gabapentin or pregabalin have stronger evidence than muscle relaxants:

• Gabapentin (initial 100-300 mg at bedtime, titrated gradually) and pregabalin (initial 50 mg three times daily or 75 mg twice daily) are first-line agents for sciatica with radiculopathy 4.
• Gabapentin requires 3-8 weeks of titration plus an additional 2 weeks at target dose to constitute an adequate therapeutic trial 4.
• Renal function must be evaluated before initiating or titrating gabapentinoids, as dose adjustments are required in renal insufficiency 4.

Critical Safety Considerations

All skeletal muscle relaxants increase central nervous system adverse events (relative risk 2.04 vs placebo), primarily sedation and dizziness:

• This markedly raises fall risk in patients with compromised mobility from cervical myelopathy or severe radiculopathy 1, 4.
• Cyclobenzaprine is chemically related to amitriptyline and carries anticholinergic effects; it does not produce true muscle relaxation despite its name 3.
• Avoid carisoprodol due to abuse potential (metabolized to meprobamate) and lack of advantage over cyclobenzaprine 4.
• Benzodiazepines (e.g., diazepam) are not recommended despite comparable efficacy, due to higher abuse potential, tolerance development, and absence of FDA approval for this indication 4.

Clinical Decision Algorithm

For Acute Neck Pain Without Radiculopathy:

• Prescribe cyclobenzaprine or another skeletal muscle relaxant for ≤2 weeks only 1, 4.
• Monitor closely for sedation, dizziness, and fall risk 4.
• Reassess after 2-3 weeks; continuation without documented benefit should prompt consideration of alternative diagnoses 4.

For Cervical Radiculopathy (Arm Pain/Numbness):

• Initiate gabapentin or pregabalin as first-line therapy 4.
• Allow adequate trial duration (5-10 weeks total including titration) before declaring treatment failure 4.
• Check renal function before starting and adjust dose accordingly 4.

For Cervical Myelopathy (Spinal Cord Compression):

• Do not rely on muscle relaxants; these patients require urgent neurosurgical evaluation 6.
• If spasticity from myelopathy is present, baclofen (a GABA-B agonist) may be considered, but this addresses spasticity from upper motor neuron dysfunction, not the underlying compression 3.

Critical Pitfalls to Avoid

• Do not combine muscle relaxants with benzodiazepines or opioids without careful risk assessment, as this substantially increases sedation and respiratory depression risk 4.
• Do not prescribe cyclobenzaprine under the assumption it relieves true muscle spasm; its mechanism is unrelated to muscle relaxation 3.
• Do not use muscle relaxants as monotherapy for chronic radicular pain; gabapentinoids are preferred based on stronger evidence 4.
• Patients who fail conservative management (including muscle relaxants) and utilize opioids have higher rates of progression to surgery; muscle relaxant use was associated with treatment failure in one large database study (n=90,037) 7.